Watch for KOMET-017 Phase 3 data readouts and potential FDA filing for the combination regimen as the next catalysts.
KURA drugs
KURA drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 2 $8.97entry
- T+1 · 6mo ago −3.51%α −2.82% · $8.66
- T+5 · 5mo ago −1.78%α +1.18% · $8.81
- T+20 · 5mo ago +20.18%α +21.74% · $10.78
- T+60 · 3mo ago +45.60%α +44.48% · $13.06
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Kura Oncology announced publication in Blood of updated Phase 1a/b KOMET-007 data for ziftomenib + venetoclax + azacitidine in relapsed/refractory NPM1-mutated AML. In venetoclax-naïve patients at the 600 mg dose, the combination showed a 70% CRc rate, 75% central MRD negativity, and median OS not reached after 10.7 months follow-up.
Key Facts
- 87% ORR and 70% CRc in venetoclax-naïve R/R NPM1-m AML patients at 600 mg ziftomenib dose
- 75% central MRD negativity (<0.01% threshold) in CRc responders with no prior venetoclax
- Median CRc duration 9.2 months; median OS not reached after 10.7 months follow-up in venetoclax-naïve
- 48% ORR and 24% CRc in venetoclax-experienced patients at 600 mg dose
- Low rates of differentiation syndrome (3%) and QTc prolongation (1 case) observed
- Ziftomenib (KOMZIFTI) is FDA-approved as monotherapy for R/R NPM1-m AML
- KOMET-017 Phase 3 trials in newly diagnosed NPM1-m and KMT2A-r AML are ongoing
Financial Impact
No financial figures provided in press release; clinical data supports potential label expansion into combination therapy, which could expand addressable market beyond monotherapy
Risk Factors
- Combination regimen is investigational and not yet FDA-approved
- Differentiation syndrome boxed warning remains a safety concern
- Competition from other menin inhibitors (e.g., Syndax's revumenib) could limit market share
- Phase 3 trials may fail to replicate Phase 1b results
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3305195 |
Track record
29 reports on KURA
5 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +52.28% at T+60 after the Jun 3, 2026 report. 9 of 13 went positive at some point.
Filters
- Nov 16, 2026today Insider Buy Bullish 5/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
- Nov 16, 2026today 144 Neutral 3/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
- Nov 10, 20266d ago S-3ASR Neutral 4/10 Entry $7.73 Now $7.09 −8.28% settles Feb 9
- Nov 10, 20266d ago Press Release Neutral 5/10 Entry $7.73 Now $7.09 −8.28% settles Feb 9
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $7.61 Now $7.09 −6.83% settles Feb 2
- Sep 29, 20266w ago Insider Cluster Bearish 5/10 Entry $10.71 Now $7.09 +33.80% settles Dec 24
- Sep 29, 20266w ago Press Release Bullish 6/10 Entry $10.81 Now $7.09 −34.38% settles Dec 23
- Sep 9, 20269w ago 8-K Bullish 6/10 Entry $12.09 Now $7.09 −41.36% settles Dec 3
- Sep 8, 20269w ago 8-K Neutral 2/10 Entry $12.52 Now $7.09 −43.37% settles Dec 2
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers